Caroline Nebhan, MD, PhD


Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Daniel Sherbenou, MD, PhD


Dr. Sherbenou on Selecting Treatment in Late Relapsed Multiple Myeloma

Daniel Sherbenou, MD, PhD, discusses selecting between available treatment options for patients with late relapsed multiple myeloma.

Jared Kaltwasser


Investigators Set Sights on Optimizing CAR T-Cell Therapy in Lymphoma

Five years since the first FDA approval of CAR T-cell therapy in relapsed/refractory lymphoma, there is still much to learn about how to optimize its use, according to Sattva S. Neelapu, MD.

Kevin Diasti, MD


Geography Should Not Be Destiny

To really advance equity in cancer care, we must think long and hard about where we apply innovation and how we measure success.

Andrei Gafita, MD


Dr. Gafita on Prognostic Models for Treatment With 177Lu-PSMA-617 in mCRPC

Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Steven J. Cohen, MD


Dr. Cohen on the Importance of Obtaining an Adequate Tissue Sample in GI Malignancies

Steven J. Cohen, MD, discusses the importance of obtaining an adequate tissue sample for molecular testing in gastrointestinal cancers.

Anne Chiang, MD, PhD, Yale Cancer Center


Future Directions in Treatment of Small Cell Lung Cancer

Panelists conclude their discussion by commenting on areas of unmet need and sharing personal perspectives on factors that may change clinical practice for SCLC in the future.

Brandon Blue, MD


Dr. Blue on the Importance of Early Intervention in Relapsed/Refractory Multiple Myeloma

Brandon Blue, MD, discusses the importance of early intervention in relapsed/refractory multiple myeloma.

Praveen Ramakrishnan, MD, MS


Dr. Ramakrishnan on the Evolving Landscape of CAR T-cell Therapy in DLBCL

Praveen Ramakrishnan, MD, MS, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma.

Stephen Freedland, MD, Cedars-Sinai Medical Center


Advanced Prostate Cancer: Remaining Challenges

Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.

Wenxin Xu, MD


Dr. Xu on Future Developments in Kidney Cancer

Wenxin Xu, MD, discusses future considerations for the treatment of patients with kidney cancer. 

Bradley J. Monk, MD, FACS, FACOG


Key Data Highlights in Ovarian Cancer

The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.

Navid Redjal, MD, FAANS


Dr. Redjal on Technological Advances in Neurosurgical Oncology

Navid Redjal, MD, FAANS, discusses technological advances that have impacted neurosurgical oncology.

Steven Vernino, MD, PhD


Clinical Pearls and the Future of LEMS

Experts provide clinical pearls on treating Lambert-Eaton myasthenic syndrome and small cell lung cancer and share upcoming advances and trials they look forward to.

Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf


Addressing Treatment Gaps in HER2+ MBC

Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.

Theresa Boyle, MD, PhD


Dr. Boyle on Approaching Biomarker Testing in Lung Cancer

Theresa Boyle, MD, PhD, discusses the current approach to biomarker testing in lung cancer.

Paul Szabolcs, MD


Rapid Readout: HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

Expert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.

Allina Health


Allina Health Cancer Institute 2022 Symposium reimagines cancer care

Allina Health Cancer Institute is excited to offer its second annual Oncology Symposium on Friday, Sept. 23, 2022. The symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.

Aileen I. Fernandez, PhD


Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

Aileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.